Insights Widest with the analysis, Proactive gives perspectives that others don't.

Zelira Therapeutics Ltd - Zelira Therapeutics accelerates transition from purely research-based to revenue-generating with Zenivol™ and HOPE™ launch in Australia by end third quarter Zelira Therapeutics accelerates transition to revenue-generation with Zenivol™ and HOPE™ launch in Australia by quarter-end

Zelira is undertaking product development programs targeting specific conditions and human...

1 week ago
Deep dive

Emerald Clinics hits record number of patients; joins global fight against...

The healthcare technology and services company joined the global fight against COVID-19 by...

1 week, 5 days ago
Deep dive

eSense-Lab achieves key milestones that validate commercialisation model for...

Life-sciences company eSense-Lab is leading the market in evidence-based terpene product...

4 weeks, 1 day ago
Deep dive

MGC Pharmaceuticals leads the way in phytocannabinoid derived medicines

The company creates premium phytocannabinoid-based products from its GMP facility in Europe that...

on 10/7/20
Deep dive

THC Global targets product range expansion and entry into Asia Pacific,...

The company has secured agreements to export into Europe, New Zealand and Canada with effect...

on 4/7/20


Emerald Clinics makes first big move into UK with Spectrum Biomedical deal

Emerald Clinics Ltd (ASX:EMD) CEO Dr Michael Winlo talks to Proactive about his company’s new partnership with Spectrum Biomedical UK to develop a real-world evidence data system in the UK. Shares in the company soared in response to the agreement which will see Emerald design and deliver...

2 days, 2 hours ago

Join Proactive

Get ahead of the curve

First with the equities news

Get our market previews and stories before the main networks.

Widest with the analysis

Not just the FTSE. Read about
opportunities from the whole
equities market.

Closest to the source

Hear directors at first-hand
or meet them in person at our events.

In at the start

Watch IPOs and access on the same terms as the institutions.